Last reviewed · How we verify
IDP-122 Lotion
At a glance
| Generic name | IDP-122 Lotion |
|---|---|
| Also known as | HP 0.01%, Lotion |
| Sponsor | Bausch Health Americas, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis (PHASE4)
- Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis (PHASE2)
- Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis (PHASE3)
- Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDP-122 Lotion CI brief — competitive landscape report
- IDP-122 Lotion updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI